The ESC Textbook of Cardiovascular Medicine – Volume 1&2 (3rd Edition)


Download The ESC Textbook of Cardiovascular Medicine – Volume 1&2 (3rd Edition) written by A. John Camm, Thomas F. Luscher, Gerald Maurer, Patrick W. Serruys in PDF format. This book is under the category Cardiology and bearing the isbn/isbn13 number 198784902/9780198784906. You may reffer the table below for additional details of the book.

Category: Tag:


Winner of the BMA Cardiology Book Award 2019

As a consistently growing knowledge base; The ESC Textbook of Cardiovascular Medicine; 3rd Edition; (PDF) together with ESC CardioMed; arms all cardiologists – from consultants and trainees to device specialists and allied healthcare professionals – with a great; multifaceted resource encompassing all features of cardiovascular medicine.

“The glory of medicine is that it is always moving ahead; that there is always more to learn. William James Mayo; 1928.”

This 3rd edition of The ESC Textbook of Cardiovascular Medicine is a wanted attempt to improve lifelong learning for cardiologists; indeed; it will be a beneficial resource for all of those members of the healthcare team devoted to the care of patients. ESC CardioMed; the new digital dimension with constant updates; is a particularly appealing feature and much needed to give timely updates on topics. Reflection on Will Mayo’s quote from 1928 at a time of comparatively slow growth in information to lead clinical practice compared to the existing rapid pace of new discoveries and ongoing analysis of clinical practice stresses the challenge for clinicians to ‘keep up’. Connecting new evidence-based data to clinical practice guidelines with advanced digital technologies is an amazing approach and will greatly improve what happens at the bedside in clinical decision-making.

Medicine is a scholarly profession; this involves a commitment to lifetime learning which is one marker of the best in our profession. We critically evaluate what we do and try to improve care for our patients with discovery; innovation; and sharing of experience. Those who uphold their scholarly endeavors; even while busily dedicated to heavy clinic practice responsibilities; will find substantial satisfaction with these ESC educational efforts. My personal view is that scholarly activity; broadly defined; is a cure for burnout among physicians. I am sure this third edition of The ESC Textbook of Cardiovascular Medicine and the ESC CardioMed digital version with updates will contribute prominently to enhancing care for the patients we serve and ease the scholarly milieu of clinical practice.

NOTE: The product includes the ebook; The ESC Textbook of Cardiovascular Medicine 3e in PDF. No access codes are included.

Additional information


A. John Camm, Thomas F. Luscher, Gerald Maurer, Patrick W. Serruys


Oxford University Press; 3rd Edition




3309 pages







Table of contents

Table of contents :
PART 1. Introduction to the cardiovascular system
Section 1. Cardiovascular history and physical examination
1.1. Approach to cardiovascular assessment, Andrew Elder, Nicholas A. Boon, and Alan G. Japp
1.2. Cardiovascular symptoms, Alan G. Japp, Iain Simpson, Stephen Pettit, Arthur Yue, and Junaid Zaman
1.3. Cardiovascular signs, Stuart Pringle, Samantha Fitzsimmons, Ingibjorg Gudmundsdottir, and Joseph B. Esterson
Section 2. Developmental biology of the heart
2.1. Cardiac embryogenesis, Robert G. Kelly
2.2. The molecular basis of cardiac embryogenesis, Miguel Torres
2.3. From heart-forming region to ballooning chambers, Maurice J. B. van den Hoff and Antoon F. M. Moorman
2.4. Development of the ventricles and valves, Jose M. Perez-Pomares and Jose L. de la Pompa
2.5. Development of the cardiac conduction system, Jan Hendrik van Weerd and Vincent M. Christoffels
2.6. Epicardial and coronary vascular development, Thomas J. Cahill and Paul R. Riley
2.7. Cardiomyocyte development from mid-gestation through preadolescence, Mark H. Soonpaa and Loren J. Field
Section 3. Functional anatomy of the heart
3.1. Introduction, Sabine Ernst and Siew Yen Ho
3.2. Cardiac anatomy in the interventional era: an overview, Ammar M. Killu and Samuel J. Asirvatham
3.3. Normal conduction system, coronary arteries, and coronary veins, Taka-aki Matsuyama and Hatsue Ishibashi-Ueda
3.4. Normal atrial and ventricular myocardial structures, Damian Sanchez-Quintana and Jose Angel Cabrera
3.5. The heart as a functional unit, Philip J. Kilner and Sonya V. Babu-Narayan
3.6. Ventricular structure and function, Philip J. Kilner and Sonya V. Babu-Narayan
3.7. Functional anatomy of atria, Luigi Badano and Denisa Muraru
3.8. Functional anatomy of left heart valves, Fahd Makhdom, Pascal Theriault-Lauzier, Siew Yen Ho, and Nicolo Piazza
3.9. Functional anatomy of right heart valves, Christine Selton-Suty, Olivier Huttin, Clement Venner, and Yves Juilliere
3.10. Functional anatomy of myocardial perfusion, Robert Manka and Sabrina Oebel
Section 4. Cardiovascular physiology
4.1. The heart as a pump: governing principles, Sandor J. Kovacs
4.2. Cardiac electrophysiology, Marek Malik
4.3. Cardiovascular physiology: regulation of coronary circulation, Christian Seiler
4.4. Regulation of blood pressure, Gino Seravalle and Guido Grassi
4.5. Heart/kidney interactions, Markus P. Schlaich
4.6. Cardiovascular response to exercise, Ross Arena, Dejana Popovic, Marco Guazzi, Amy McNeil, and Michael Sagner
4.7. Cardiovascular response to mental stress, Jens Barthelmes and Isabella Sudano
4.8. The cardiovascular system during sleep, Naima Covassin and Virend K. Somers
4.9. The ageing heart, Magnus Back, Laure Joly, Nicolas Sadoul, and Athanase Benetos
4.10. Alterations in cardiovascular physiology in pathological states, Sebastian Ewen, Saarraaken Kulenthiran, and Felix Mahfoud
Section 5. Cardiovascular pharmacology
5.1. Renin-angiotensin system and neprilysin, Joao Pedro Ferreira and Patrick Rossignol
5.2. Mineralocorticoid receptor antagonists, Faiez Zannad and Joao Pedro Ferreira
5.3. Autonomic nervous system drugs, Atul Pathak
5.4. Pharmacology of vasodilators, Stephane Laurent
5.5. Positive inotropes, Mattia Arrigo and Alexandre Mebazaa
5.6. Antiarrhythmics, Federico Guerra and Alessandro Capucci
5.7. Pharmacology of oral antiplatelet drugs, Tabassome Simon
5.8. Fibrinolytic therapy, Freek W. A. Verheugt
5.9. Lipid-lowering drugs, Cesare R. Sirtori and Massimiliano Ruscica
5.10. Oral diabetes treatments and cardiovascular disease, Pierre-Jean Saulnier and Samy Hadjadj
5.11. Renal pharmacology for the cardiologist, Kevin Damman
5.12. Potassium binders, Keld P. Kjeldsen, Juan Tamargo, and Thomas Andersen Schmidt
5.13. Cardiovascular effects of non-cardiovascular drugs, Pauline Bosco-Levy, Julien Bezin, Francesco Salvo, and Nicholas Moore
5.14. Drug-drug interactions, Jeffrey K. Aronson
5.15. Local drugs in interventional cardiology pharmacology, Jonathan Michel and Robert A. Byrne
Section 6. Anticoagulation
6.1. An overview of haemostasis, in relation to atherothrombotic, thromboembolic, and venous cardiovascular disease, Pier Mannuccio Mannucci
6.2. Current targets of anticoagulants, Fedor Bachmann
6.3. Epidemiology of non-vitamin K antagonist oral anticoagulants in heart disease, Renate Schnabel, Dipak Kotecha, and Paulus Kirchhof
6.4. Unfractionated heparin, Freek W. A. Verheugt
6.5. Low-molecular-weight heparin, Paul Guedeney, Mathieu Kerneis, Johanne Silvain, Gilles Montalescot, and Jean-Philippe Collet
6.6. Fondaparinux and its derivatives, Michiel Coppens
6.7. Bivalirudin and argatroban, Davide Capodanno
6.8. Reversal of parenteral anticoagulants, Marcel Levi
6.9. Vitamin K antagonists, Jorgen Jespersen and Jane Skov
6.10. The NOACs: pharmacodynamics and pharmacokinetics, Thomas Vanassche and Peter Verhamme
6.11. The NOACs: clinical pharmacology, Jeffrey Weitz
6.12. The NOACs in special situations: the elderly, renal impairment, combination with antiplatelet agents and thrombolytics, Felicita Andreotti, Eliano Pio Navarese, and Filippo Crea
6.13. Reversal of oral anticoagulants, Joanne van Ryn
6.14. Epidemiological data on the use of traditional anticoagulants in cardiovascular disease, Christina Reith and Colin Baigent
Section 7. Epidemiology and global burden
7.1. Strategies for assessment of global disease burden, Sumeet S. Chugh
7.2. Epidemiology and global burden of hypertension, George A. Mensah
7.3. Epidemiology and global burden of ischaemic heart disease, Andrew E. Moran
7.4. Epidemiology and global burden of cardiomyopathy, James D. Wilkinson, Ashwin Kumar, Joslyn A. Westphal, Jason D. Czachor, Hiedy Razoky, and Steven E. Lipshultz
7.5. Epidemiology and global burden of arrhythmias, Aapo L. Aro and Sumeet S. Chugh
7.6. Epidemiology and global burden of rheumatic heart disease, Dianne Sika-Paotonu, Andrea Beaton , and Jonathan Carapetis
7.7. Epidemiology and global burden of myocarditis and pericarditis, Siva Ketha and Leslie T. Cooper
7.8. Epidemiology and global burden of infective endocarditis, Imad M. Tleyjeh and Aref A. Bin Abdulhak
7.9. Epidemiology and global burden of peripheral arterial disease and aortic aneurysms, Holger Reinecke
PART 2. Investigations
Section 8. Electrocardiogram
8.1. Introduction, Antonio Bayes de Luna
8.2. Atrial abnormalities, Adrian Baranchuk and Bryce Alexander
8.3. Ventricular hypertrophy, Ljuba Bacharova and Harvey Estes
8.4. Intraventricular conduction disturbances, Antonio Bayes de Luna and Marcelo Elizari
8.5. ECG patterns of ischaemia and necrosis, Miguel Fiol and Antonio Bayes de Luna
8.6. ECG patterns related to arrhythmias and sudden death: channelopathies, early repolarization, and preexcitiation, Wojciech Zareba and Pyotr Platonov
8.7. ECG in syncope, palpitations, dyspnoea, and chest pain, Angel Moya
8.8. The abnormal ECG without apparent heart disease and the normal ECG in serious heart diseases: two extremes, Antonio Bayes de Luna and Gunter Breithardt
8.9. Ambulatory ECG monitoring, Iwona Cygankiewicz
Section 9. Chest radiography
9.1. Normal anatomy with a focus on the cardiac silhouette and the great vessels, Christian Loewe and Dietrich Beitzke
9.2. Pulmonary venous hypertension, Massimo Pistolesi and Mariaelena Occhipinti
9.3. Pulmonary arterial hypertension and acute and chronic thromboembolism, Thomas Henzler
9.4. Pulmonary infections, Tomas Franquet
9.5. Focal abnormalities, Nicola Sverzellati, Gianluca Milanese, and Mario Silva
9.6. Lines, tubes, and implantable devices, Nicholas Screaton and Gianluca Milanese, and Mario Silva
Section 10. Cardiac ultrasound
10.1. Principles of echocardiographic imaging and velocity assessment by Doppler and speckle tracking, Jens-Uwe Voigt
10.2. Technical equipment for echocardiography, Thomas Binder
10.3. Transthoracic echocardiography and the standard examination of specific cardiac structures, Thomas Binder
10.4. Stress echocardiography, Roxy Senior and Nikolaos Karogiannis
10.5. Contrast echocardiography, Anastasia Vamvakidou and Roxy Senior
10.6. Three-dimensional echocardiography, Francesco F. Faletra, Laura A. Leo, Tiziano Moccetti, and Mark J. Monaghan
10.7. Coronary heart disease, Thomas H. Marwick
10.8. Hypertension and diabetes, Laura Ernande
10.9. Transoesophageal echocardiography, Ruxandra Beyer and Frank A. Flachskampf
10.10. Left ventricular function, heart failure, and resynchronization therapy, Jens-Uwe Voigt
10.11. Assist devices, Satoshi Nakatani
10.12. Cardiomyopathies, myocarditis, and the transplanted heart, Thor Edvardsen
10.13. Cardiac valves, Damien Voilliot and Patrizio Lancellotti
10.14. Echocardiography in transcatheter aortic valve implantation, Mehdi Eskandari and Mark J. Monaghan
10.15. Transcatheter mitral valve repair: from edge-to-edge to annuloplasty, Mehdi Eskandari and Mark J. Monaghan
10.16. Prosthetic valve evaluation, Felix C. Tanner and Rolf Jenni
10.17. Pulmonary hypertension and the right ventricle, Petros Nihoyannopoulos and Julia Grapsa
10.18. Echocardiographic assessment: diseases of the aorta, Arturo Evangelista and Jose Rodriguez-Palomares
10.19. Atrial fibrillation, cardiogenic embolism, and tumors, Bogdan Popescu, Maria-Magdalena Gurzun, and Carmen Ginghina
10.20. Emergency echocardiography, Aleksandar N. Neskovic, Ivan Stankovic, and Predrag Milicevic
Section 11. Cardiovascular magnetic resonance
11.1. Normal anatomy and function, Alicia Maceira
11.2. Cardiovascular magnetic resonance physics, techniques, and contrast agents, Sonia Nielles-Vallespin
11.3. Coronary artery disease, Jurg Schwitter
11.4. Cardiomyopathies, Matthias Friedrich and Fabian Siepen
11.5. Congenital heart disease, Sonya Babu-Narayan
11.6. Valvular heart disease, Saul Myerson
11.7. Atherosclerosis imaging, Chun Yuan, Zach Miller, and Jianming Cai
11.8. Angiography, Jan Bogaert
11.9. Cardiovascular magnetic resonance in less common pathologies, Massimo Lombardi and Antonia Camporeale
Section 12. Cardiovascular computed tomography
12.1. Technology of cardiac computed tomography, Stephan Achenbach
12.2. Coronary calcium, Todd C. Villines, Joshua Mitchell, and Michael K. Cheezum
12.3. Coronary computed tomography angiography: detection of coronary artery stenosis, Koen Nieman
12.4. Coronary computed tomography angiography: imaging of coronary atherosclerotic plaque, Pal Maurovich-Horvat
12.5. Computed tomography myocardial perfusion, Amita Singh, Noreen Nazir, Victor Mor-Avi, and Amit R. Patel
12.6. Computed tomography for cardiac morphology, function, and valve disease, Victoria Delgado
12.7. Computed tomography for cardiac interventions, Mohamed Marwan and Stephan Achenbach
Section 13. Nuclear cardiology and positron emission tomography
13.1. Basic principles and technological state of the art: SPECT, Alessia Gimelli and Riccardo Liga
13.2. Basic principles and technological state of the art: PET, Frank Bengel
13.3. Basic principles and technological state of the art: hybrid imaging, Ronny R. Buechel and Aju P. Pazhenkottil
13.4. Assessment of coronary artery disease: chronic stable angina, Juhani Knuuti, S. Richard Underwood, and Antti Saraste
13.5. Assessment of coronary artery disease: imaging-guided management and therapy, Juhani Knuuti, S. Richard Underwood, and Antti Saraste
13.6. Integration of stress nuclear imaging in the diagnostic and management algorithms of stable coronary artery disease, Danilo Neglia and Juhani Knuuti
13.7. Assessment of coronary artery disease: nuclear myocardial perfusion imaging in specific patient populations, Danilo Neglia and Juhani Knuuti
13.8. Heart failure, Danilo Neglia and Oliver Gaemperli
13.9. Endocarditis and device infection, Fabien Hyafil, Dominique Le Guludec, and Oliver Gaemperli
13.10. Infiltrative disease (amyloidosis/sarcoidosis), Tobias A. Fuchs and Oliver Gaemperli
13.11. Future potential, Philipp A. Kaufmann, Oliver Gaemperli, and Juhani Knuuti
Section 14. Invasive imaging and haemodynamics
14.1. Haemodynamic data, Guy Heyndrickx and Carlo Di Mario
14.2. Coronary Angiography and Ventriculography, Carlo Di Mario, Serafina Valente, and Carlotta Sorini Dini
14.3. Intravascular ultrasound imaging, Philip Dingli, Nicola Ryan, Nieves Gonzalo, and Javier Escaned
14.4. Optical coherence tomography, Francesco Prati, Laura Gatto, Enrico Romagnoli, and Luca Di Vito
14.5. Near-infrared spectroscopy, Carlo Di Mario, Carlotta Sorini Dini, and Serafina Valente
14.6. Functional coronary assessment: fractional flow reserve, Emanuele Barbato and Fabio Mangiacapra
14.7. Functional coronary assessment: instantaneous wave-free ratio and other indices, Justin Davies and Christopher Cook
Section 15. Selection of imaging techniques
15.1. Choice of imaging techniques, Jeroen J. Bax, Alexander R. van Rosendael, Laurens F. Tops, Nina Ajmone Marsan, and Victoria Delgado
PART 3. Heat Diseases
Section 16 Genetics of cardiovascular diseases
16.1. Introduction, Heribert Schunkert
16.2. Genetic counselling, Jodie Ingles, Charlotte Burns, and Laura Yeates
16.3. Principles of cascade screening, Eric Sijbrands
16.4. Principles of molecular genetic testing, Eric Schulze-Bahr
16.5. Basic principles of genetic disease, Eric Schulze-Bahr
16.6. Monogenic and oligogenic cardiovascular diseases: genetics of arrhythmias-long QT syndrome, Andrea Mazzanti, Riccardo Maragna, and Sylvia Priori
16.7. Monogenic and oligogenic CV diseases – Genetics of arrhythmias – short QT Syndrome, Erol Tulumen and Martin Borggrefe
16.8. Monogenic and oligogenic CV diseases – Genetics of arrhythmias – Brugada Syndrome, Sonia Van Dooren, Dorien Daneels, Gudrun Pappaert, Maryse Bonduelle, and Pedro Brugada Terradellas
16.9. Monogenic and oligogenic CV diseases – Genetics of arrhythmias – catecholaminergic polymorphic ventricular tachycardia, Peter Schwartz and Lia Crotti
16.10. Post-mortem genetic testing in sudden death cases, Najim Lahrouchi, Elijah Behr, and Connie Bezzina
16.11. Genetics of cardiomyopathies – Hypertrophic cardiomyopathy, Philippe Charron and Carole Maupain
16.12. Genetics of cardiomyopathies – Dilated cardiomyopathy, Daniel Oehler, Benjamin Meder, and Hugo Katus
16.13. Genetics of cardiomyopathies: left ventricular non-compaction, Eloisa Arbustini, Alessandro Di Toro, Lorenzo Giuliani, Nupoor Narula, Valentina Favalli
16.14. Genetics of cardiomyopathies – Arrhythmogenic Right Ventricular Cardiomyopathy, Kalliopi Pilichou, Cristina Basso, Rudy Celeghin, and Gaetano Thiene
16.15. Genetics of cardiomyopathies: cardiac manifestations of genetic mitochondrial diseases, Abdallah Fayssoil
16.16. Genetics of cardiomyopathies – Myocardial infiltration, Frank Weidemann
16.17. Genetics of vascular disease: Marfan syndrome and aortic disease, Dorien Schepers and Bart Loeys
16.18. Structural diseases of the heart – Genetics of congenital heart diseases, Daniela Barge-Schaapveld, Marco DeRuiter, Conny van Munsteren, and Monique Jongbloed
16.19. Structural diseases of the heart: syndromes affecting the cardiovascular system, Sabine Klaassen
16.20. Complex Cardiovascular Diseases – Atherosclerosis – genetic factors, Heribert Schunkert
16.21. Complex Cardiovascular Diseases – Dyslipidaemias – genetic factors, Daniel Swerdlow, Steve Humphries, and Michael Holmes
16.22. Complex cardiovascular diseases: genetic determinants of atrial fibrillation, Patrick Ellinor and Steven Lubitz
16.23. Complex cardiovascular diseases: the genetics of arterial hypertension, Georg Ehert
Section 17. Congenital heart disease in children and adults
17.1. Introduction, John Deanfield
17.2. Nomenclature, John Deanfield and Robert Andersen
17.3. Epidemiology and incidence, John Deanfield and Bernard Keavney
17.4. Aetiology, genes, and environment, Bernard Keavney and Elisavet Fotiou
17.5. Fetal circulation & perinatal programming, Marietta Charakida
17.6. Clinical Presentations & Initial Investigations, John Deanfield
17.7. Echocardiography, Jan Marek, Folkert Meijboom, and Luc Mertens
17.8. Cross-Sectional imaging/modelling, Giovanni Biglino, Silvia Schievano, and Andrew Taylor
17.9. Functional Testing, Alessandro Giardini
17.10. Electrophysiological abnormalities and Arrhythmias, Henry Chubb and Martin Lowe
17.11. Interventional catheterization, Shakeel Qureshi
17.12. Long term Outcomes, Michiel Winter, Berto Bouma, Barbara Mulder
17.13. Arterial Disease in the Young, Marietta Charakida
17.14. Contraception and pregnancy, Jolien Roos-Hesselink and Lucia Baris
17.15. Pulmonary Hypertension, Shahin Moledina
17.16. Heart Failure, Marc Gewillig
17.17. Support/Transplantation, Dilveer Panesar and Mike Burch
17.18. Atrial septal defect, Marc Gewillig
17.19. Atrioventricular septal defect, Michelle Carr
17.20. Ventricular septal defect, Orla Franklin
17.21. Patent ductus arteriosus, Robert Yates
17.22. Pulmonary valve stenosis, Robert Yates
17.23. Vascular Rings, Robert Yates
17.24. Aortic stenosis and left ventricular outflow tract obstruction, David Anderson
17.25. Coarctation, Marietta Charakida
17.26. Tetralogy of Fallot, Robert Yates
17.27. Ebstein’s Anomaly, Sachin Khambadkone
17.28. Hypoplastic left heart syndrome, Alessandro Giardini
17.29. Single ventricle/total cavopulmonary connection (Fontan circulation), Marc Gewillig
17.30. Total anomalous pulmonary venous connection, Marietta Charakida and John Deanfield
17.31. Complete transposition of the great arteries, John Deanfield and Marietta Charakida
17.32. Congenitally corrected transposition of the great arteries, Robert Yates and Marietta Charakida
Section 18. Prevention in cardiovascular disease and rehabilitation
18.1. Introduction, Massimo Piepoli
18.2. Cardiovascular risk estimation at the individual level, Yvo M. Smulders, Marie-Therese Cooney, and Ian Graham
18.3. Risk factor management at the level of the individual using lifestyle changes, Guy De Backer, Johan De Sutter, and Ian M. Graham
18.4. Risk factor intervention at the population level, Eva Prescott, Torben Jorgensen, Maja-Lisa Lochen, Jonathan Pearson-Stuttard, Simon Capewell, and Maja Lisa Lochen
18.5. Cardiac rehabilitation and exercise training, Ugo Corra
18.6. Prevention in cardiovascular disease and rehabilitation, Ugo Corra
18.7. Settings and stakeholders, Christi Deaton, Margaret Cupples, and Kornelia Kotseva
Section 19. Diabetes mellitus and metabolic syndrome
19.1. Introduction, Lars Ryden
19.2. Dysglycaemia – Definition, classification and diagnosis, Jaakko Tuomilehto and Lars Ryden
19.3. Vascular complications of dysglycaemia, Francesco Cosentino
19.4. Cardiovascular risk assessment in diabetes and pre-diabetes, Nikolaus Marx
19.5. Preventing cardiovascular complications in patients with dysglycemia, Linda Mellbin and Lars Ryden
19.6. Special conditions – Acute coronary syndromes, Baris Gencer and Marco Roffi
19.7. Special conditions – Revascularisation, Miguel Sousa Uva
19.8. Diabetes and heart failure, Karl Swedberg
19.9. Diabetes and arrhythmias, Heikki Huikuri and Lars Ryden
19.10. Diabetes and lower extremity arterial disease, Lucia Mazzolai, Marianne Brodmann, and Victor Aboyans
19.11. Special conditions: kidney disease, Henrik Per Groop and Drazenka Pongrac Barlovic
19.12. Person centred care, Asa Hornsten
Section 20. Heart and the brain
20.1. Acute ischaemic stroke: classification and diagnosis, Hans-Christoph Diener
20.2. Impact of stroke on heart function, Christoph Kleinschnitz
20.3. Causes of cardioembolic stroke, Stefan Hohnloser
20.4. Embolic stroke of undetermined source, Hans-Christoph Diener
20.5. Treatment of acute stroke, Heinrich P. Mattle and Simon Jung
20.6. Closure of a patent foramen ovale for the prevention of stroke, David R. Holmes Jr, Guy S. Reeder, and Heinrich Mattle
20.7. Secondary stroke prevention in patients with atrial fibrillation, Hans-Christoph Diener
20.8. Management of vascular risk factors and co-morbidities in secondary stroke prevention, Martin O’Donnell and Cliona Small
20.9. Intracranial haemorrhage in patients with atrial fibrillation on anticoagulants, Heinrich Mattle, Marcel Arnold, and Urs Fischer
20.10. Atrial Fibrillation and dementia, Hans-Christoph Diener and John Camm
Section 21. Cardiovascular problems in chronic kidney disease
21.1. Epidemiology and chronic kidney disease as a cardiovascular risk factor, Stephan Segerer and Harald Seeger
21.2. Causes of death in renal disease, Thomas F. Mueller and Valerie Luyckx
21.3. Pathophysiology, Christoph Wanner
21.4. Cardiovascular imaging in chronic kidney disease, Victoria Delgado
21.5. Prevention and drug therapy in chronic kidney disease, Stephan Segerer and Harald Seeger
21.6. Device therapy in chronic kidney disease (implantable cardioverter defibrillator, cardiac resynchronization therapy), Petra Nijst and Wilfried Mullens
21.7. Special considerations in patients undergoing renal replacement therapy and kidney transplant patients, Thomas F. Mueller and Valerie Luyckx
Section 22. Erectile dysfunction
22.1. Sex and the heart, Piero Montorsi
22.2. Erectile dysfunction: definition and size of the problem, Michael Doumas and Chrysoula Boutari
22.3. Asking, Tiny Jaarsma
22.4. Erectile dysfunction as a marker and predictor of cardiovascular disease, Charalambos Vlachopoulos and Nikolaos Ioakeimidis
22.5. Testosterone, erectile dysfunction, and the heart, Geoffrey Hackett
22.6. Sexual function and dysfunction in women (and the effect for the couple), Kevan R. Wylie
22.7. Lifestyle issues, Michael Kirby
22.8. Drugs, Mike Kirby and Jonny Coxon
22.9. Surgery, Odunayo Kalejaiye, Amr Abdel Raheem, and David Ralph
22.10. Management of a patient with erectile dysfunction with or without known cardiovascular disease, Charalambos Vlachopoulos, Nikolaos Ioakeimidis, and Dimitris Tousoulis
Section 23. Lung Disease
23.1. Epidemiological relationships between respiratory and cardiovascular diseases, Kieran Rothnie and Jennifer Quint
23.2. Long Term Oxygen Therapy/Ventilation and Cardiovascular outcomes in chronic lung and respiratory disease, Antia Simonds
23.3. Effect of chronic obstructive pulmonary disease treatment on cardiovascular outcome, Jennifer Quint
23.4. Muscle weakness in chronic obstructive pulmonary disease and heart failure, Michael Polkey
23.5. Pulmonary rehabilitation in Chronic Lung Disease and Heart Failure, William Man and Rachael Evans
23.6. Sleep apnoea: definition, prevalence and role in cardiovascular diseases, Olaf Oldenburg
23.7. Sleep Related Breathing Disorders – Classification and diagnosis, Melissa Lipford and Virend Somers
23.8. Sleep apnoea: treatment options and sleep/cardiovascular outcome, Holger Woehrle and Michael Artz
23.9. Beyond positive airway pressure therapy: experimental and non-conventional treatments in sleep apnoea, Bernardo Selim
23.10. Atmospheric pollution and cardiovascular risk, Mark Miller, Anoop Shah, Nicholas Mills, and Dave Newby
23.11. High-altitude pulmonary oedema, Samuel Verges and Patrick Levy
Section 24. Gastrointestinal disease
24.1. Introduction, Gerhard Rogler
24.2. Gut microbiome, metabolic syndrome, and atherosclerosis, Eduard F. Stange
24.3. Gut microbiota and coronary artery disease, Slayman Obeid, Melroy Miranda, and Thomas F. Lüscher
24.4. The gut and cardiovascular diseases, Giuseppe Rosano
24.5. Intestinal absorption and drug levels, Gerd A. Kullak-Ublick and Regina Krattinger
24.6. Chronic heart failure and liver function, Felix Stickel, Matteo Montani, and Christian Datz
24.7. Protein-losing enteropathy associated with heart disease, Conall Morgan and Luc Mertens
Section 25. Rheumatoid arthritis and the heart
25.1. Introduction, Thomas F. Lüscher
25.2. Mechanisms of inflammation, Roland Klingenberg and Ulf Muller-Ladner
25.3. Inflammatory diseases: inflammation and cardiovascular disease, Luigi Marzio Biasucci and Giovanna Liuzzo
25.4. Rheumatoid arthritis: basic mechanisms in joints, Oliver Distler and Caroline Ospelt
25.5. Anti-inflammatory therapies for cardiovascular disease, Thomas F. Lüscher and Paul M. Ridker
25.6. Treatment aims in rheumatoid arthritis, Oliver Distler and Adrian Ciurea
25.7. Inflammatory bowel disease: basic mechanisms, Gerhard Rogler
25.8. Inflammatory bowel disease and the heart, Christian M. Matter, Stephan Winnik, and Gerhard Rogler
25.9. Psoriasis, Alexander A. Navarini
Section 26. Rheumatic heart disease
26.1. Introduction, Ferande Peters
26.2. Epidemiology of acute rheumatic fever and rheumatic heart disease, Liesl Zuhlke
26.3. Pathogenesis: from acute rheumatic fever to rheumatic heart disease, Liesl Zuhlke
26.4. Clinical features and diagnosis of acute rheumatic fever, Antoinette Cilliers
26.5. Echocardiography in acute rheumatic fever and rheumatic heart disease, Ferande Peters, Ruchika Meel, and Mohammed R. Essop
26.6. Prevention and definitive therapy of acute rheumatic fever, Liesl Zuhlke
26.7. Chronic rheumatic disease, Ferande Peters, Mpiko Ntsekhe, and Mohammed Essop
26.8. Clinical scenarios in chronic rheumatic heart disease, Mohammed Essop, Mpiko Ntsekhe, and Ferande Peters
26.9. Therapeutic options in chronic rheumatic heart disease, Mohammed Essop
Section 27. Cardio-oncology
27.1. Introduction, John Groarke
27.2. Radiation-induced heart disease: surveillance and management, Ersilia M. DeFilippis and Anju Nohria
27.3. Surveillance for cardiotoxicity in patients receiving potentially cardiotoxic chemotherapy, Cian P. McCarthy, Michael T. Osborne, and Tomas G. Neilan
27.4. Anthracycline-related cardiotoxicity: epidemiology, surveillance, prophylaxis, management, and prognosis, Daniela Cardinale and Carlo Maria Cipolla
27.5. Trastuzumab-related cardiotoxicity: epidemiology, surveillance, management, prophylaxis, and prognosis, Torbjorn Omland
27.6. Cardiovascular complications of novel kinase inhibitors, Mark Sweeney and Alexander Lyon
27.7. Cardiovascular complications of novel multiple myeloma treatments, Daniel J. Lenihan
27.8. Cardiovascular risk in men with prostate cancer, Daniel Perry, Megan Caram, and Monika Leja
27.9. Cardiac arrhythmias and cancer therapies, John Keaney
Section 28. HIV
28.1. Introduction, Nombulelo P. Magula and Akira Singh
28.2. Epidemiology of HIV-associated cardiovascular complications, Giuseppe Barbaro
28.3. HIV-associated cardiomyopathy and myocarditis, Ntobeko A. B. Ntusi
28.4. Pericarditis and myopericarditis in HIV, Rubeshan Perumal and Nombulelo P. Magula
28.5. Vascular disease: coronary, stroke, and peripheral vascular disease, Darrin Ryan Naidoo and Sherlina Kasipersad
28.6. Pulmonary hypertension: definitions, classification, diagnosis, and management, Anastase Dzudie and Friedrich Thienemann
28.7. Antiretroviral treatment, Nombulelo P. Magula, Rubeshan Perumal, and Ruffin Apalata
Section 29. Acute coronary syndromes
29.1. Introduction, Stefan James and Marco Roffi
29.2. The plaque, Michael Joner and Philipp Nicol
29.3. Epidemiology of acute coronary syndromes, Hector Bueno
29.4. General risk factors of acute coronary syndromes, Lene Rorholm Pedersen and Eva Prescott
29.5. Pathophysiology of acute coronary syndromes, Giovanna Liuzzo, Daniela Pedicino, and Filippo Crea
29.6. Thrombotic response, Robert Storey and William Parker
29.7. Development of myocardial infarction, Pascal Vranckx
29.8. Diagnosis and risk stratification of acute coronary syndromes, Christian Mueller
29.9. Treatment of non-ST elevation acute coronary syndromes, Marco Valgimigli and Marco Angelillis
29.10. Treatment of ST-segment elevation acute coronary syndromes, Borja Ibanez and Sigrun Halvorsen
Section 30. Takotsubo syndrome
30.1. Introduction, Christian Templin
30.2. Incidence and definition of takotsubo syndrome, Abhiram Prasad
30.3. Mechanisms of takotsubo syndrome, Leonarda Galiuto and Filippo Crea
30.4. Signal transduction pathways initiated by catecholamines in takotsubo syndrome: focus on nitrosative stress and energetic impairment, John D. Horowitz, Thanh Ha Nguyen, Sven Y. Surikow, Gao Jing Ong, Cher-Rin Chong, Dana K. Dawson, and Michael P. Frenneaux
30.5. Triggers of takotsubo syndrome, Jelena R. Ghadri
30.6. Clinical presentation of takotsubo syndrome, Ilan Wittstein
30.7. Diagnostic testing in takotsubo syndrome, Rodolfo Citro and Eduardo Bossone
30.8. ECG features and arrhythmias in takotsubo syndrome, Federico Migliore, Sebastiano Gili, and Domenico Corrado
30.9. Co-morbidities in takotsubo syndrome, Ken Kato, Sebastiano Gili, Fabio Fabbian, and Roberto Manfredini
30.10. Management of takotsubo syndrome, John E. Madias
30.11. Takotsubo syndrome complications, outcome, and prognosis, Scott W. Sharkey
Section 31 Chronic ischaemic heart disease
31.1. Introduction, William Wijns
31.2. Pathology of Stable Coronary Artery Disease, Michael Joner, Kristin Steigerwald, and Anna Bulin
31.3. Pathophysiology of coronary circulation, Nils Johnson and K. Gould
31.4. Myocardial ischaemia: definition and causes, Filippo Crea and Gaetano Lanza
31.5. Importance of the Coronary Collateral Circulation, Christian Seiler
31.6. Coronary artery disease: from atherosclerosis to obstructive disease, inducible ischaemia, and the ischaemic cascade, Jeroen Bax
31.7. Clinical symptoms of stable ischaemic heart disease, Ulrich Fischer-Rasokat and Christian Hamm
31.8. Non invasive functional evaluation, Juhani Knuuti and Antti Saraste
31.9. Invasive and non-invasive (computed tomography) angiography, Stephan Achenbach
31.10. Invasive functional evaluation, Keith Oldroyd and Colin Berry
31.11. Intracoronary imaging, Nicola Ryan, Nieves Gonzalo, and Javier Escaned
31.12. Risk stratification and risk scores, Vasim Farooq, Patrick Serruys, and Ply Chichareon
31.13. Medical management: lifestyle and behavioural changes, Nicolas Danchin, Etienne Puymirat, and Nadia Aissaoui
31.14. Medical management: pharmacological therapy, Aviv Shaul and David Hasdai
31.15. Myocardial revascularization: symptomatic and prognostic indications, Jean Claude Tardif, Philippe L’Allier, and Fabien Picard
31.16. Cost Effectiveness, Ruben Osnabrugge and Pieter Kappetein
31.17. Patient Reported Outcome Measures in Cardiovascular Disease, Ran Kornowski and Eli Lev
31.18. Ischaemic heart disease and diabetes, Ruben Osnabrugge and Pieter Kappetein
31.19. Percutaneous coronary intervention versus coronary artery bypass grafting, Daniele Giacoppo and Robert Byrne
31.20. Refractory angina, Alessia Azzano and Stefan Verheye
31.21. Chronic ischaemic cardiomyopathy, Ward Heggermont, Marc Vanderheyden, and Jozef Bartunek
31.22. Microvascular angina, Paolo Camici and Ornella Rimoldi
31.23. Vasospastic angina, Peter Ong and Udo Sechtem
Section 32. Myocardial disease
32.1. Introduction, Perry Elliott
32.2. Classification of cardiomyopathies, Eloisa Arbustini, Valentina Favalli, Alessandro Di Toro, Alessandra Serio, and Jagat Narula
32.3. General approach to diagnosis of cardiomyopathies, Claudio Rapezzi and Massimiliano Lorenzini
32.4. Hypertrophic cardiomyopathy: genetics, Mohammed Akhtar and Luis Lopes
32.5. Hypertrophic cardiomyopathy: diagnosis and assessment of symptoms, Albert Hagege
32.6. Hypertrophic cardiomyopathy: medical management of heart failure symptoms and arrhythmias, Iacopo Olivotto
32.7. Hypertrophic cardiomyopathy: invasive management of left ventricular outflow tract obstruction, Steve Omen
32.8. Hypertrophic cardiomyopathy: prevention of sudden cardiac death, Constantinos O’Mahony
32.9. Dilated cardiomyopathy: genetics, Luis Lopes
32.10. Dilated Cardiomyopathy – Clinical diagnosis and medical management, Gianfranco Sinagra, Marco Merlo, and Davide Stolfo
32.11. Dilated cardiomyopathy: management of arrhythmia and prevention of sudden cardiac death, Pier Lambiase and Rui Providencia
32.12. Restrictive cardiomyopathy, Jens Mogensen
32.13. Arrhythmogenic right ventricular cardiomyopathy: genetics, Petros Syrris and Alexandros Protonotarios
32.14. Arrhythmogenic right ventricular cardiomyopathy: diagnosis, Cristina Basso, Barbara Bauce, and Gaetano Thiene
32.15. Arrhythmogenic right ventricular cardiomyopathy: management of symptoms and prevention of sudden cardiac death, Perry Elliott and Alexandros Protonotarios
32.16. Left ventricular non-compaction: genetics and embryology, Pablo Garcia-Pavia and Fernando Dominguez
32.17. Left ventricular non-compaction: diagnosis and clinical management, Jens Mogensen and Torsten B. Rasmussen
32.18. Myocarditis – Aetiology & histopathological diagnosis, Sabine Pankuweit
32.19. Myocarditis – Clinical presentation, Alida Caforio, Renzo Marcolongo, and Sabino Iliceto
32.20. Myocarditis: imaging techniques, Ali Yilmaz and Anca Florian
32.21. Myocarditis – Treatment of myocarditis, Peter Heinz Schultheiss and Felicitas Escher
32.22. The heart in neuromuscular disease: primary mitochondrial diseases, Denis Duboc
32.23. The heart in neuromuscular disease: myotonic dystrophy, Henning Bundgaard, Anna Axelsson, Alex Christensen, and Helle Petri
32.24. The Heart in Neuromuscular disease – Duchenne and Limb Girdle Muscular Dystrophies, Karim Wahbi
32.25. The heart in inherited metabolic disorders: lysosomal and glycogen storage diseases, Ales Linhart
32.26. Cardiac Amyloidosis, Martha Grogan
32.27. Peripartum Cardiomyopathy, Karen Sliwa and Denise Hilfiker-Kleiner
32.28. Childhood cardiomyopathy, Juan Kaski and Gabrielle Norrish
Section 33. Pericardial disease
33.1. Overview of pericardial syndromes, Michael Arad and Yehuda Adler
33.2. Acute and recurrent pericarditis, Massimo Imazio, Fiorenzo Gaita, and Yehuda Adler
33.3. Pericardial effusion, Antonio Brucato and Stefano Maggiolini
33.4. Cardiac tamponade, Arsen D. Ristic, Petar M. Seferovic, Bernhard Maisch, and Vladimir Kanjuh
33.5. Constrictive pericarditis, Antonis Pantazis, Karin Klingel, and Yishay Wasserstrum
33.6. Pericardial masses and congenital abnormalities, Angelos G. Rigopoulos and Hubert Seggewiss
33.7. Pericardial involvement in neoplastic disease, Dor Lotan and Yehuda Adler
33.8. Multimodality imaging of pericardial diseases, Massimo Imazio and Fiorenzo Gaita
33.9. Interventional therapies for pericardial diseases, Bernhard Maisch, Arsen Ristic, Sabine Pankuweit, and Peter Seferovic
33.10. Surgical therapies for pericardial disease, George Krasopoulos
33.11. What nexta
Section 34. Tumours of the heart
34.1. Masses and cardiac tumours: classification and diagnosis, Gaetano Thiene, Stefania Rizzo, Martina Perazzolo Marra, Marialuisa Valente, and Cristina Basso
34.2. Benign cardiac tumours, Cristina Basso, Stefania Rizzo, Martina Perazzolo Marra, Marialuisa Valente, and Gaetano Thiene
34.3. Malignant tumours, pericardial tumours, and therapy, Cristina Basso, Stefania Rizzo, Marialuisa Valente, Martina Perazzolo Marra, and Gaetano Thiene
Section 35. Valvular heart disease
35.1. Introduction and general comments, Bernard Lung and Pieter Kappetein
35.2. Aortic regurgitation, Pilar Tornos Mas and Emmanuel Lansac
35.3. Aortic stenosis, Helmut Baumgartner and Thomas Walther
35.4. Mitral regurgitation, Raphael Rosenhek and Michele de Bonis
35.5. Mitral stenosis, Alec Vahanian
35.6. Tricuspid regurgitation, Patrizio Lancellotti and Michele de Bonis
35.7. Tricuspid stenosis, Michele DeBonis
35.8. Combined and multiple valve diseases, Michele DeBonis
35.9. Prosthetic valves, Bernard Iung and Johan Sjogren
35.10. Management during non-cardiac surgery, Johan Holm and Bernard Iung
35.11. Management during pregnancy, Johan Holm and Bernard Iung
Section 36. Infective endocarditis
36.1. Epidemiology and physiopathology, Bernard Iung
36.2. Diagnosis, Nuria Fernandez-Hidalgo, Maria Nazarena Pizzi, and Pilar Tornos
36.3. Prognosis and complications, Isidre Vilacosta and Carmen Olmos
36.4. Prosthetic valve endocarditis, Jose A. San Roman and Javier Lopez
36.5. Cardiac device-related endocarditis, Maria Grazia Bongiorni and Andrea Di Cori
36.6. Right-sided infective endocarditis, Jose A. San Roman and Javier Lopez
36.7. Non-bacterial thrombotic endocarditis, Patrizio Lancellotti and Stella Marchetta
36.8. Congenital heart disease, Joey M. Kuijpers, Berto J. Bouma, and Barbara J. M. Mulder
36.9. Indications for surgery: guidelines, Gilbert Habib
36.10. Surgical techniques, Jean-Francois Obadia, Benoit Cosset, and Matteo Pozzi
36.11. Antibiotic prophylaxis and prevention of infective endocarditis, Bruno Hoen and Xavier Duval
36.12. Conclusion and future directions, Gilbert Habib
Section 37. Heart failure
37.1. Epidemiology of Heart Failure, Theresa McDonagh and Kaushik Guha
37.2. Definition, epidemiology, and burden of disease: HFrEF, Pietro Aldo Maggioni and Ovidiu Chioncel
37.3. Definition, epidemiology, and burden of disease: HFpEF, Lars Lund and Gianluigi Savarese
37.4. Definitions: quality of life, health, and health-related quality of life, Anna Stromberg and Tiny Jaarsma
37.5. Chronic heart failure diagnosis: symptoms, signs, and the ECG, Pardeep Jhund
37.6. Chronic heart failure diagnosis: HFpEF, Sanjiv Shah and Daniel Silverman
37.7. Chronic heart failure diagnosis: echocardiography, Thomas Marwick
37.8. Chronic heart failure diagnosis: cardiovascular magnetic resonance imaging, Robert Manka and Sabrina Oebel
37.9. Chronic heart failure diagnosis – Biomarkers, Christian Mueller
37.10. Chronic heart failure diagnosis – Genetics, Perry Elliott
37.11. Estimating prognosis – Prognostic scores, Vasiliki Bistola, John Parissis, and Gerasimos Filippatos
37.12. Estimating prognosis – Biomarkers, Arthur Richards
37.13. Comorbidity (HFrEF and HFpEF) – Atrial fibrillation, Dipak Kotecha and Mitja Lainscak
37.14. Co-morbidity (HFrEF and HFpEF): diabetes mellitus, Mark Petrie and Kieran Doherty
37.15. Co-morbidity (HFrEF and HFpEF): hypertension, Francesco Paneni and Massimo Volpe
37.16. Comorbidity (HFrEF and HFpEF) – Renal dysfunction, Kevin Damman
37.17. Comorbidity (HFrEF and HFpEF) – Anaemia/iron deficiency, Piotr Ponikowski
37.18. Co-morbidity (HFrEF and HFpEF): obesity, cachexia, sarcopenia, and the impact of nutrition, Stefan Anker and Stephan von Haeling
37.19. Comorbidity (HFrEF and HFpEF) a Lung disease
37.20. Comorbidity (HFrEF and HFpEF) – Sleep disordered breathing, Martin Cowie
37.21. Comorbidity (HFrEF and HFpEF) – Cancer, Thomas Suter
37.22. Co-morbidity (HFrEF and HFpEF): valvular heart disease, Luc Pierard
37.23. HFrEF pharmacological treatment: diuretics, Rhondalyn Forde-McLean and Mariell Jessup
37.24. HFrEF pharmacological treatment: ACEIs and/or ARBs, Marc Pfeffer
37.25. HFrEF pharmacological treatment: angiotensin receptor-neprilysin inhibitors, John McMurray
37.26. HFrEF pharmacological treatment: beta blockers, Simon Beggs and Roy Gardner
37.27. HFrEF pharmacological treatment – Ivabradine, Michel Komajda
37.28. HFrEF pharmacological treatment: digitalis glycosides, John Cleland and Yura Mareev
37.29. HFrEF pharmacological treatment – Hydralazine and isosorbide dinitrate, Faraz Ahmad and Clyde Yancy
37.30. HFrEF other treatment: indications and results of implantable cardioverter defibrillator and cardiac resynchronization therapy, Valentina Kutyifa
37.31. HFrEF other treatment – Revascularization, Eric Velazquez and Mark Petrie
37.32. HFrEF other treatment: ventricular assist devices, Randall Starling and Emer Joyce
37.33. Advanced Heart Failure other treatment – Transplantation, Peter MacDonald and Kumud Dhital
37.34. HFrEF other treatment: nurse-led heart failure management programmes, Anna Stromberg and Tiny Jaarsma
37.35. HFpEF treatment – Pharmacological therapy, Maja Cikes and Scott Solomon
37.36. Patient monitoring in heart failure, Dirk van Veldhuisen
37.37. Exercise rehabilitation in heart failure, Alan Cohen-Solal
37.38. Palliative care in heart failure, James Beattie
37.39. Acute heart failure – Diagnosis, Adriaan Voors and Piotr Ponikowski
37.40. Acute heart failure – Immediate management/stabilization, Javier Martin-Sanchez, Oscar Miro, and Hector Bueno
37.41. Acute heart failure – Treatment, Dimitrios Farmakis, John Parissis, and Gerasimos Filippatos
Section 38. Bradycardia
38.1. Introduction, Giuseppe Boriani
38.2. Aetiology and epidemiology of bradyarrhythmias, Fredrik Glader and Cinzia Valzania
38.3. Classification of bradyarrhythmias, Bulent Gorenek and Gulmira Kudaiberdieva
38.4. Methods and tools for the diagnosis of intermittent and persistent bradycardia, Georges H. Mairesse
38.5. Anatomy and physiology of the sinus node, Antonio Zaza
38.6. The sinus node: normal and abnormal chronotropic response and drug effects, Bruce Wilkoff and Corey Coleman
38.7. Sinus node disease: pathophysiology and natural history, Jonathan M. Kalman and Gwilym M. Morris
38.8. Sinus node disease: ECG patterns and diagnosis, Tatjana Potpara
38.9. Sinus node disease: the role of electrophysiological testing, Dominic A. M. J. Theuns
38.10. Atrial tachyarrhythmias in bradycardiaatachycardia syndrome: characterization and evolution
38.11. Anatomy and physiology of the atrioventricular node, M. J. Pekka Raatikainen
38.12. Atrioventricular conduction abnormalities and atrioventricular blocks: ECG patterns and diagnosis, S. Serge Barold
38.13. Atrioventricular conduction abnormalities and atrioventricular blocks: role of electrophysiology testing, Demosthenes G. Katritsis and Mark E. Josephson
38.14. Congenital atrioventricular blocks: clinical presentation, clinical evaluation, and management, Drago Fabrizio and Battipaglia Irma
38.15. Carotid sinus syndrome: clinical presentation, diagnosis, and management, Richard Sutton
38.16. Bradycardia in athletes: clinical evaluation and management, Hein Heidbuchel
38.17. Cardiac pacing: basic concepts, Renato Pietro Ricci
38.18. Temporary pacing, Alexander Bauer
38.19. Permanent cardiac pacing in bradyarrhythmias: device coding, Bela Merkely
38.20. Pacing for bradycardia: device features and algorithms and clinical impact, Jens Cosedis Nielsen and Jens Kristensen
38.21. Electrocardiographic patterns of cardiac pacemakers: normal and abnormal findings, Carsten Israel
38.22. Follow-up of pacemaker patients with bradyarrhythmias: scope of follow-up and organizational issues, Anne M. Gillis
38.23. Pacemakers in children and adolescents, Johannes Sperzel
38.24. Lead management, Jean Claude Deharo
38.25. Electromagnetic interference in pacemaker patients, Jan Steffel
38.26. Pacemaker syndrome, Giuseppe Boriani and Igor Diemberger
Section 39. Syncope
39.1. Definition, epidemiology, classification, and pathophysiology, J. Gert van Dijk and Roland D. Thijs
39.2. Diagnostic evaluation, Frederik J. de Lange and J. Gert van Dijk
39.3. Reflex syncope, Jean-Claude Deharo
39.4. Cardiac syncope, Richard Sutton
39.5. Orthostatic intolerance: orthostatic hypotension and postural orthostatic tachycardia syndrome, Artur Fedorowski
39.6. Unexplained syncope in patients with high risk of sudden cardiac death, Vincent Probst and Jean-Baptiste Gourraud
39.7. Recommendations of the European Society of Cardiology Guidelines for the diagnosis and management of syncope (version 2018), Michele Brignole
Section 40. Supraventricular tachycardias
40.1. Introduction, Carina Blomstrom-Lundqvist
40.2. Epidemiology of supraventricular tachycardias, Gregory Y. H. Lip
40.3. Atrial premature beats, Tatjana Potpara
40.4. Definitions, clinical presentation, symptoms, quality of life, and patient preferences, Tatjana Potpara
40.5. Differential diagnosis of supraventricular tachycardias, Haran Burri
40.6. Acute management of supraventricular tachycardias with and without established diagnosis (termination and/or rate regulation of tachycardia), Isabel Deisenhofer
40.7. Management of rapid heartbeats/tachycardias with rhythm or rate control in the absence of ECG-verified diagnosis, Isabel Deisenhofer
40.8. Management of specific supraventricular tachycardias, Isabel Deisenhofer
40.9. Sinus node-related tachycardias: physiological sinus tachycardia, inappropriate sinus tachycardia, sinus node reentrant tachycardia, and postural orthostatic tachycardia syndrome, Brian Olshansky
40.10. Atrial tachycardias: focal and multifocal atrial tachycardias, Pierre Jais and Nicolas Derval
40.11. Atrial tachycardias: macroreentrant atrial tachycardias, CTI-dependent atrial flutter (clockwise, anticlockwise), and non-CTI-dependent macroreentrant atrial tachycardia, Jose L. Merino
40.12. Atrioventricular nodal reentrant tachycardia, Demosthenes G. Katritsis
40.13. Accessory pathways-related tachycardias: Wolff-Parkinson-White syndrome and atrioventricular reentrant tachycardias, Jonathan Chrispin and Hugh Calkins
40.14. Concealed accessory pathways and related tachycardias, Carlo Pappone and Vincenzo Santinelli
40.15. Pre-excitation related to Mahaim physiology, Carlo Pappone and Vincenzo Santinelli
40.16. Asymptomatic pre-excitation, Jonathan Chrispin and Hugh Calkins
40.17. Permanent junctional reciprocating tachycardia, Hildegard Tanner
40.18. Non-reentrant junctional tachycardias, Demosthenes G. Katritsis
40.19. Health economy, Giuseppe Boriani
Section 41. Atrial fibrillation
41.1. Introduction, A. John Camm
41.2. Epidemiology, Emelia Benjamin and Darae Ko
41.3. Mechanisms of atrial fibrillation: electrophysiological basis, Ulrich Schotten
41.4. Mechanisms of atrial fibrillation: genetics, David O. Arnar and Hilma Holm
41.5. Mechanisms of atrial remodelling, David R. Van Wagoner
41.6. Types of atrial fibrillation, Larissa Fabritz, Ulrich Schotten, and Paulus Kirchhof
41.7. Silent atrial fibrillation, Ben Freedman and Nicole Lowres
41.8. Atrial fibrillation progression and prevention, Justin G. L. M. Luermans, Jordi Heijman, Isabelle C. Van Gelder, and Harry J. G. M. Crijns
41.9. Clinical investigation of patients presenting with atrial fibrillation, Hein Heidbuchel
41.10. Management of acute presentation with atrial fibrillation rate control, Christian Sticherling and Michael Kuehne
41.11. Restoration of sinus rhythm: direct current cardioversion, Riccardo Cappato
41.12. Pharmacological cardioversion for atrial fibrillation, Irina Savelieva
41.13. Rate control: medical therapy, Isabelle C. Van Gelder, Michiel Rienstra, Laurent Pison, and Harry J. G. M. Crijns
41.14. Rate control: ablation and device therapy (ablate and pace), Maurizio Gasparini and Paola Galimberti
41.15. Rhythm control: antiarrhythmic drugs, Juan Tamargo
41.16. Development of atrial fibrillation catheter ablation and ablation strategies, Gerhard Hindricks, Nikolaos Dagres, Philipp Sommer, and Andreas Bollmann
41.17. Rhythm control: surgical ablation, Chawannuch Ruaengsri, Matthew R. Schill, Richard B. Schuessler, and Ralph J. Damiano, Jr
41.18. Rate versus rhythm control therapy for atrial fibrillation, Albert L. Waldo
41.19. Follow-up of patients with atrial fibrillation, Jeroen Hendriks
41.20. Stroke risk factors and risk stratification in atrial fibrillation, Gregory Y. H. Lip
41.21. Stroke prevention in atrial fibrillation, Michael D. Ezekowitz and Amanulla N. Khaji
41.22. Bleeding risk in anticoagulated patients with atrial fibrillation, Margaret C. Fang
41.23. Thromboprophylaxis in atrial fibrillation: device therapy and surgical techniques, Thorsten Lewalter, Clemens Jilek, and Peter Sick
41.24. Classification and mechanisms of atrial flutter, Eric M. Riles and Melvin Scheinman
41.25. Atrial flutter: clinical presentation, Bhupesh Pathik and Jonathan M. Kalman
41.26. Atrial flutter: management, Tilman Maurer, Christine Lemes, and Karl-Heinz Kuck
41.27. Atrial fibrillation and heart failure, Johannes Brachmann
41.28. Atrial fibrillation and athletes, Eduard Guasch and Lluis Mont
41.29. Atrial fibrillation in the elderly, David Hirsh and Nanette Wenger
41.30. Atrial fibrillation after cardiopulmonary surgery, Rohan S. Wijesurendra and Barbara Casadei
41.31. Atrial fibrillation and hypertension, Hung-Fat Tse and Jo-Jo Hai
41.32. Atrial fibrillation and hyperthyroidism, Bernadette Biondi
41.33. Atrial fibrillation and obesity, Rajiv Mahajan, Dennis H. Lau, and Prashanthan Sanders
41.34. Atrial fibrillation and sleep apnoea and chronic obstructive pulmonary disease, Jared D. Miller and Hugh G. Calkins
41.35. Atrial fibrillation and chronic kidney disease, Ken Okumura and Hirofumi Tomita
41.36. Atrial fibrillation in pregnancy, Jamie Conti, Mark Panna, and Michael Kaufmann
41.37. Atrial fibrillation associated with adult congenital heart disease, Sunil Kapur and Saurabh Kumar
41.38. Integrated care management in atrial fibrillation, Jeroen Hendriks
41.39. Patient education, Deirdre A. Lane
Section 42. Ventricular tachycardia
42.1. Classification of ventricular tachycardias, Nishant Verma and Bradley P. Knight
42.2. Evaluation and acute management of wide QRS complex tachycardia, Sei Iwai and Jason Jacobson
42.3. Classification and treatment of non-sustained ventricular tachycardia, Alfred E. Buxton
42.4. Sustained monomorphic ventricular tachycardia associated with structural heart disease: classification, assessment, and initial treatment, Fernando M. Contreras-Valdes and Peter J. Zimetbaum
42.5. Bundle branch reentry tachycardia, Akihiko Nogami
42.6. Electrical storm, Len Ganz
42.7. Sustained monomorphic ventricular tachycardia: the role of catheter ablation, Tilman Maurer,William G. Stevenson, and Karl-Heinz Kuck
42.8. Sustained and non-sustained ventricular tachycardia and no associated heart disease (idiopathic ventricular tachycardia), Victor Bazan, Enrique Rodriguez-Font, and Francis E. Marchlinski
42.9. Polymorphic ventricular tachycardias including torsade de pointes, L. Brent Mitchell
Section 43. Sudden Cardiac Death
43.1. Epidemiology and underlying substrates, Harry Rakowski and Arnon Adler
43.2. Arrhythmic mechanisms of sudden cardiac death: bradycardia and tachycardia, Pedro Brugada Terradellas and Juan Sieira
43.3. Risk stratification for sudden cardiac death in the general population, Efstathios Iliodromitis and Dimitrios Farmaksis
43.4. Risk stratification for sudden cardiac death in ischaemic cardiomyopathy, Nikolaos Dagres and Gerhard Hindricks
43.5. Risk stratification for sudden cardiac death in dilated cardiomyopathy, Dietmar Baensch
43.6. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy, Wilhelm Haverkamp and Philipp Attanasio
43.7. Risk stratification for sudden cardiac death in arrhythmogenic right ventricular cardiomyopathy, Firat Duru and Corinna Brunckhorst
43.8. Risk stratification for sudden cardiac death in primary electrical disorders, Peter J. Schwartz and Lia Crotti
43.9. New techniques for risk assessment in sudden cardiac death, Juan Fernandez-Armenta, Antonio Berruezo, Juan Acosta, and Diego Penela
43.10. Prevention of sudden cardiac death in the general population, Efstathios Iliodromitis and Dimitrios Farmaksis
43.11. Prevention of sudden cardiac death in ischaemic cardiomyopathy, Luigi Di Biase, Jorge Romero, Andrea Natale, Ricardo Avendano, and Mario Garcia
43.12. Secondary prevention of sudden cardiac death in ischaemic cardiomyopathy, Jens Cosedis Nielsen and Jens Kristensen
43.13. Primary prevention of sudden death in idiopathic dilated cardiomyopathy, Riccardo Cappato
43.14. Secondary prevention of sudden death in idiopathic dilated cardiomyopathy, Riccardo Cappato
43.15. Primary prevention of sudden cardiac death in hypertrophic cardiomyopathy, Barry Maron
43.16. Secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy, Wilhelm Haverkamp and Philipp Attanasio
43.17. Primary prevention of sudden cardiac death in arrhythmogenic right ventricular cardiomyopathy, Katja Zeppenfeld and Sebastiaan Piers
43.18. Secondary prevention of sudden cardiac death in arrhythmogenic right ventricular cardiomyopathy, Katja Zeppenfeld and Sebastiaan Piers
43.19. Secondary prevention of sudden cardiac death after catheter ablation of ventricular tachycardia, Josep Brugada and Elena Arbelo
43.20. Prevention of sudden cardiac death in primary electrical disorders, Josep Brugada and Elena Arbelo
43.21. The implantable cardioverter defibrillator, conclusions on sudden cardiac death, and future perspective, Arash Arya
Section 44. Systemic hypertension
44.1. Epidemiology and Pathophysiology of Hypertension, Stefano Taddei, Rosa Bruno, Masi Stefano, and Anna Solini
44.2. Blood pressure measurement in hypertension: definition and classification of blood pressure levels, Gianfranco Parati
44.3. Target organ damage, cardiovascular disease risk, and clinical evaluation of the hypertensive patient, Giovanni De Simone
44.4. Secondary causes of hypertension, Isabella Sudano
44.5. Blood pressure Thresholds for treatment and blood pressure treatment targets in hypertension, Bryan Williams
44.6. Sodium and potassium intake, blood pressure and cardiovascular prevention, Francesco P Cappuccio
44.7. Drug treatment of hypertension, Michel Burnier, Sverre Kjeldsen, Anthony Heagerty, and Bryan Williams
44.8. Device based treatment for hypertension, Felix Mahfoud
44.9. Hypertension in Specific conditions / comorbidities, Enrico Agabiti Rosei, Maria Lorenza Muiesan, and Massimo Salvetti
44.10. Hypertension in Special situations, Thomas Kahan
Part 4 Vascular disease
Section 45. Pulmonary Hypertension
45.1. Introduction, Marc Humbert
45.2. Pulmonary hypertension: definition, Stephan Rosenkranz
45.3. Pulmonary hypertension: epidemiology, Rogerio Souza, Jose Leonidas Alves, and Susana Hoette
45.4. Pathophysiologic Mechanisms in Pulmonary Hypertension, Christophe Guignabert, Ly Tu, Alice Huertas, and Marc Humbert
45.5. Pulmonary hypertension genes as major diagnostic tools, Florent Soubrier, Melanie Eyries, Barbara Girerd, David Montani, David Tregouet, and Marc Humbert
45.6. Mechanisms of right ventricular failure, Joanne Groeneveldt, Anton Vonk Noordegraaf, and Frances de Man
45.7. Clinical Presentation of Pulmonary Hypertension, Marion Delcroix and Catharina Belge
45.8. Life-threatening complications of pulmonary hypertension, Marion Delcroix and Catharina Belge
45.9. Pulmonary hypertension: clinical classification, Rogerio Souza, Francisca Oleas, and Caio Fernandes
45.10. Echocardiographic findings in pulmonary hypertension, Adam Torbicki
45.11. Screening for pulmonary arterial hypertension, John Coghlan
45.12. Diagnosis and clinical Investigation of patients presenting with pulmonary hypertension, Rogerio Souza, Daniela Calderaro, and Luis Felipe Prada
45.13. Management of pulmonary hypertension – Basic treatment, Stephan Rosenkranz
45.14. Management of pulmonary hypertension: targeted therapies, Nazzareno Galie, Alessandra Manes, and Massimiliano Palazzini
45.15. Management of pulmonary hypertension – Treatment algorithm, Nazzareno Galie, Alessandra Manes, and Massimiliano Palazzini
45.16. Lung transplantation in pulmonary arterial hypertension, Laurent Savale
45.17. Idiopathic pulmonary arterial Hypertension, Rogerio Souza, Carlos Jardim, and Luciana Morinaga
45.18. Heritable pulmonary arterial Hypertension, Nicholas Morrell and Charaka Hadinnapola
45.19. Pulmonary arterial Hypertension induced by drugs and toxins, Irene Lang and Meinhard Kneussl
45.20. Pulmonary arterial Hypertension associated with connective tissue disease, Chris Denton
45.21. Portopulmonary Hypertension, Olivier Sitbon and Laurent Savale
45.22. Pulmonary arterial Hypertension associated with congenital heart diseases, Michael Gatzoulis, Margarita Brida, and Michel Gatzoulis
45.23. Pulmonary Arterial Hypertension associated with HIV infection, Olivier Sitbon
45.24. Pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatois, David Montani, Barbara Girerd, Edmund Lau, and Marc Humbert
45.25. Pulmonary hypertension due to left heart diseases, Jean-Luc Vachiery
45.26. Pulmonary hypertension due to chronic lung diseases, Ari Chaouat, Anne Guillaumot, Emmanuel Gomez, Olivier Huttin, Christine Suty-Selton, and Francois Chabot
45.27. Chronic thromboembolic pulmonary hypertension, Gerald Simonneau
45.28. ‘Group 5’ pulmonary hypertension due to multiple and/or unclear mechanisms, Andrew Peacock
45.29. Referral centres and patient education, Simon Gibbs
45.30. Genetic counselling in pre-capillary pulmonary hypertension, David Montani, Barbara Girerd, and Marc Humbert
45.31. Risk assessment and treatment goals in patients presenting with pulmonary arterial hypertension, Marius Hoeper
45.32. Conclusion, Marc Humbert
Section 46. Diseases of the aorta
46.1. Introduction, Raimund Erbel
46.2. The normal aorta, Raimund Erbel
46.3. Aortic aneurysm – Thoracic aortic aneurysm – Diagnostic approach, Oliver Gaemperli and Udo Sechtem
46.4. Aortic aneurysm – Thoracic aortic aneurysm – Therapeutic options, Axel Haverich and Andreas Martens
46.5. Aortic aneurysm – Aortic arch aneurysms, Roberto Bartolomeo, Alessandro Leone, Luca Di Marco, and Davide Pacini
46.6. Aortic aneurysm – Abdominal aortic aneurysm – Diagnostic Approach, Regula von Allmen
46.7. Aortic aneurysm – Abdominal aortic aneurysm – Therapeutic options, Regula von Allmen
46.8. Aortic sclerosis – Clinical signs and diagnosis, Yuvrajsinh Parmar and I. Kronzon
46.9. Aortic sclerosis – Therapy, Raimund Erbel
46.10. Acute aortic syndrome – Diagnostic strategy and clinical features, Riccardo Gorla, Eduardo Bossone, and Raimund Erbel
46.11. Acute aortic syndrome: emerging role of biomarkers, Toru Suzuki, Riccardo Gorla, and Eduardo Bossone
46.12. Acute aortic syndrome – Aortic dissection – Ascending aortic dissection, Christoph Starck, Robert Hammerschmidt, and Volkmar Falk
46.13. Acute aortic syndrome – Aortic dissection – Descending aortic dissection, Rachel Clough, Xun Yuan, and Chirstoph Nienaber
46.14. Acute aortic syndrome – Intramural Haematoma, Jae-Kwan Song
46.15. Penetrating aortic ulcer, Arturo Evangelista and Jose Rodriguez-Palomares
46.16. Acute aortic syndrome – Traumatic aortic injury, Johnny Steuer and Mario Lachat
46.17. Acute aortic syndrome – latrogenic aortic trauma, Ivan Nunez-Gil and Gisela Feltes
46.18. Genetic diseases of the aorta – Chromosomal and inherited diseases, Dorien Schepers and Bart Loeys
46.19. Genetic diseases of the aorta: aortic diseases related to Marfan syndrome and other genetic abnormalities, Bernard Lung
46.20. Genetic diseases of the aorta – Aortic diseases associated with bicuspid aortic valves, Folkert Meijboom and Gertjan Sieswerda
46.21. Aortitis – infectious and non-infectious diseases, Rosangela Cocchia, Riccardo Gorla, and Eduardo Bossone
46.22. Aortic tumor, Francesca Urgnani and Vicente Riambau
46.23. Long-term follow-up in patients with aortic diseases, Udo Sechtem and Oliver Gaemperli
46.24. Aortic centres, Raimund Erbel
Section 47. Trauma to the cardiovascular system
47.1. Trauma to the cardiovascular system, Ibrahim Akin and Christoph A. Nienaber
Section 48. Non-cardiac surgery
48.1. Introduction and epidemiology, Hans Erik Botker
48.2. Preoperative evaluation: surgical risk for cardiac events and functional capacity risk indices, Jose Gonzalez-Juanatey
48.3. Preoperative evaluation – Biomarkers, Emmanuelle Duceppe and P.J. Devereaux
48.4. Preoperative evaluation – Non Invasive testing, Juhani Knuuti and Antti Saraste
48.5. Preoperative evaluation – Angiography, Hans Erik Botker
48.6. Risk reduction strategies: perioperative management of cardiovascular medication, Emmanuelle Duceppe and P.J. Devereaux
48.7. Risk reduction strategies: perioperative management in patients on antithrombotic therapy, Steen Kristensen, Michael Maeng, and Kurt Huber
48.8. Risk reduction strategies: coronary revascularization before non-cardiac surgery, Marco Roffi and Fabio Rigamonti
48.9. Specific diseases: chronic heart failure/hypertension, Rodrigo Modolo and Ana Paula de Faria
48.10. Specific diseases: valvular heart disease, Bernard Iung and Luc Pierard
48.11. Specific diseases: arrhythmias, Susanna Price and Evi Christodoulou
48.12. Specific diseases: renal disease, Susanna Price
48.13. Specific diseases: stroke, Marco Roffi
48.14. Specific diseases: pulmonary diseases, Susanna Price
48.15. Perioperative monitoring: transoesophageal echocardiography, Luc Pierard
48.16. Perioperative Monitoring – Right Heart catherization, Susanna Price
48.17. Perioperative monitoring: glycaemic control, Susanna Price
48.18. Perioperative monitoring: anaesthesiology, Stefan De Hert
48.19. Conclusions and recommendations, Juhani Knuuti and Antti Saraste
Section 49. Peripheral arterial diseases
49.1. Introduction, V Aboyans
49.2. Epidemiology and risk factors, Marie-Louise Bartelink
49.3. General aspects, Lucia Mazzolai
49.4. Antithrombotic drugs in peripheral arterial diseases, Jean Philippe Collet
49.5. Extracranial carotid and vertebral artery disease, Ross Naylor
49.6. Upper extremity artery disease, Tina Conhert
49.7. Mesenteric artery disease, Martin Bjorck
49.8. Renal artery disease, Charalambos Vlachopoulos
49.9. Lower extremity artery disease, Marianne Brodmann
49.10. Multisite artery disease, Marco DeCarlo
49.11. Cardiac conditions in peripheral arterial diseases, Michal Tendera
49.12. Gaps in evidence, JB Ricco
Section 50. Venous thromboembolism
50.1. Introduction, Stavros Konstantinides
50.2. Epidemiology and socioeconomic consequences of venous thromboembolism, Alexander Cohen, Marjolein Brekelmans, and Carlos Martinez
50.3. Predisposing factors for first and recurrent venous thrombosis, Willem Lijfering and Suzanne Cannegieter
50.4. Pathophysiology of acute pulmonary embolism, Dieuwertje Ruigrok and Anton Vonk Noordegraaf
50.5. Diagnosis – clinical prediction rules and laboratory tests, Piotr Pruszczyk
50.6. Diagnosis of acute pulmonary embolism and evolving imaging modalities, Helia Robert-Ebadi, Gregoire Le Gal, and Marc Righini
50.7. Prognostic assessment, Cecilia Becattini and Giancarlo Agnelli
50.8. Treatment – haemodynamic and respiratory support, Thomas Vanassche and Peter Verhamme
50.9. Treatment – anticoagulation, Cecilia Becattini and Giancarlo Agnelli
50.10. Treatment – thrombolysis, Guy Meyer
50.11. Treatment: catheter-based intervention and inferior vena cava filters, Ronald Winokur and Akhilesh Sista
50.12. Management of pulmonary embolism in pregnancy, Thijs van Mens and Saskia Middeldrop
50.13. Management of pulmonary embolism in patients with cancer, Cihan Ay and Florian Posch
50.14. Risk of recurrence and optimal duration of anticoagulation, Marc Rodger, Lisa Duffett, and Faizan Khan
50.15. Chronic thromboembolic pulmonary hypertension, Irene Lang,Walter Klepetko, and Hiromi Matsubara
Section 51. Venous disease
51.1. Epidemiology and classification of venous disease, Eberhard Rabe and Felizitas Pannier
51.2. Imaging for venous thrombosis, Frederikus Klok, Charlotte Dronkers, and Menno Huisman
51.3. Venous recanalisation, Jochen Grommes
51.4. Varicose veins, Roshan Bootun, Tristan Lane, and Alun H. Davies
51.5. Chronic venous insufficiency and post-thrombotic syndrome, Robert Eberhardt and Joseph Raffetto
PART 5. Specific populations – gender and race
Section 52. Cardiovascular disease in women
52.1. Background, JoAnn E. Manson and Mariana Garcia
52.2. Sex and gender differences overview, Eva Prescott
52.3. Traditional cardiovascular disease risk factors, Karin Schenck-Gustafsson
52.4. Non-traditional cardiovascular disease risk factors unique to or predominant in women, Angela H. E. M. Maas
52.5. Cardiovascular disease prevention guidelines, Janet Wei
52.6. Ischaemic heart disease in women, Martha Gulati
52.7. Heart failure in women, Vera Regitz-Zagrosek
52.8. Valvular heart disease, Sharon Mulvagh
52.9. Cardiac rehabilitation, Puja K. Mehta
52.10. Peripheral arterial disease in women, Mariana Garcia
52.11. Future directions, C. Noel Bairey Merz
Section 53. Pregnancy and heart disease
53.1a. General considerations, Janet Wei and C. Noel Bairey Merz
53.1b. Pregnancy risk assessment, Petronella Pieper
53.2. Gynaecological, obstetric, and neonatological aspects, Lisa-Antonia Droege and Wolfgang Henrich
53.3a. Congenital heart disease and pulmonary hypertension, Jolien Roos-Hesselink and Annemien van den Bosch
53.3b. Aortic diseases, Bernard Iung
53.4. Valvular heart disease, Petronella G. Pieper and Bernard Iung
53.5. Ischaemic heart disease in pregnancy, Angela H. E. M. Maas
53.6. Arrhythmias in pregnancy, Bozena Ostrowska, Barbara Kommata, Helena Malmborg, and Carina Blomstrom Lundqvist
53.7. Cardiomyopathies and heart failure, Vera Regitz-Zagrosek
53.8. Hypertensive disorders, Renata Cifkova
53.9. Venous thromboembolism in the peripartum period, Karen Sliwa and Mark R. Johnson
53.10. Drugs during pregnancy and breastfeeding, Stefan Verlohren
Section 54. Ethnicity
54.1. Global perspectives of hypertension and cardiovascular disease, Amitava Banerjee
54.2. Ethnicity and cardiovascular risk factors, Nizal Sarrafzadegan and Farzad Masoudkabir
54.3. Ethnicity and coronary artery disease, Adam Timmis
54.4. Ethnicity and hypertension, Bert-Jan van den Born and Charles Agyemang
54.5. Ethnicity and cardiac arrhythmias, Tatjana Potpara
54.6. Ethnicity and heart failure, Amitava Banerjee
54.7. Ethnicity and inherited cardiac disease, Larissa Fabritz
54.8. Ethnic differences in responses to cardiovascular drugs, Bernard M. Y. Cheung and Esther W. Chan
PART 6. Other aspects
Section 55. Sports and heart disease
55.1. Cardiovascular adaptation to exercise and sport (according to type of sport, gender, and ethnicity), Michael Papadakis and Sanjay Sharma
55.2. Clinical assessment of the athleteas heart: normal and abnormal ECGs in athletes
55.3. Imaging testing for differential diagnosis of the athlete’s heart from structural cardiac diseases, Antonio Pelliccia and Stefano Caselli
55.4. Sudden cardiac death in athletes: implications for pre-participation evaluation and safety in sport arenas, Eduard Guasch, Hein Heidbuchel, and Lluis Mont
55.5. Exercise and sport in the management of cardiovascular diseases (ischaemic heart disease, heart failure, and hypertension), Massimo Piepoli
Section 56. Elderly
56.1. Multimorbidity and polypharmacy in the elderly with cardiovascular diseases, Tomasz Grodzicki, Karolina Piotrowicz, and Jonna Sulicka
56.2. Palliative and end-of-life care in elderly subjects with cardiovascular disease, Piotr Sobanski
56.3. Dementia and cardiovascular diseases, Timo Strandberg and Tuomo Nieminen
56.4. Frailty, sarcopenia, and falls in cardiovascular disease, Antonio Cherubini and Massimiliano Fedecostante
56.5. Socioeconomic issues and cardiovascular disease (with emphasis on the caregivers), Nicola Veronese, Ludovico Carrino, and Stefania Maggi
56.6. Comprehensive geriatric assessment in cardiovascular disease, Andreas Schoenenberger
56.7. Degenerative cardiovascular disease in elderly, Edgar Argulian
56.8. Lessons from European Society of Cardiology Guidelines, Stefano Rimoldi
56.9. Arterial stiffness: from isolated systolic hypertension to syncope, Jerzy Gasowski, Chirag Bavishi, and Franz Messerli
56.10. Arterial stiffness: from isolated systolic hypertension to syncope, Joanna Kostka, Malgorzata Koziarska-Rosciszewska, and Tomasz Kostka
56.11. Interventions in the elderly: special considerations, Adrian Messerli and Khaled Ziada
Section 57. Precision medicine
57.1. Personalized medicine: an introduction, Paulus Kirchhof
57.2. Personalized management of coronary artery disease, T. Kessler and Heribert Schunkert
57.3. Disease mechanisms guiding therapy, Karin Sipido and Tom Guzik
57.4. Personalised management of atrial fibrillation, Larissa Fabritz, Eduard Guasch, Moritz Sinner, and Paulus Kirchhof
57.5. Individualized valve therapy, Stephan Baldus and Henrik ten Freyhaus
57.6. Genetically-modified animals as tools to personalize the study of arrhythmia mechanisms and treatment, Marina Cerrone, Morten Schak Nielsen, and Mario Delmar
57.7. Opportunities for personalized approaches in heart failure, Simon de Denus, Marie-Pierre Dube, and Jean-Claude Tardif
57.8. Personalized Therapies for Cardiac Channelopathies, Andrea Mazzanti and Silvia Priori
Section 58. Decision-making and Heart Team
58.1. The Heart Team: introduction, Vasim Farooq and Patrick W. Serruys
58.2. Heart Teams in coronary artery disease, Vasim Farooq
58.3. Decision-making and Heart Teams in valvular heart disease: the transcatheter aortic valve implantation team model, Mohammad Abdelghani, Fahd Makhdom, and Nicolo Piazza
58.4. Heart Teams in atrial fibrillation, Manuel Castella, Hans-Christoph Diener, Gerhard Hindricks, and Paulus Kirchhof
58.5. Heart Teams in grown-up congenital heart disease, Mohammad Abdelghani, Martina Nassif, Nico A. Blom, David R. Koolbergen, Barbara J. M. Mulder, and Robbert J. de Winter
58.6. The Heart Team: conclusions and future perspectives, Andras P. Durko, Stuart J. Head, and David P. Taggart
Section 59. Psychological factors and heart disease
59.1. Introduction, Susanne Pedersen
59.2. Psychological factors and incident heart disease, Susanne Pedersen
59.3. Psychological impact of heart disease, Frank Doyle
59.4. Impact of psychological factors on outcomes, Nina Kupper and Johan Denollet
59.5. Mechanisms: psychological factors and outcomes, Roland von Kaenel and Christian Albus
59.6. The wider psychosocial context, Johan Denollet
59.7. Interventions: what works for whom?, Matt Burg
59.8. Clinical implications and future perspectives, Kim Smolderen
59.9. Conclusions, Susanne Pedersen
59.10. Likely developments over the next 5-10 years, Susanne Pedersen
59.11. Personal perspective, Susanne Pedersen
Section 60. Interpretation of clinical trials
60.1. Trial Design from a Clinical Perspective, John Cleland
60.2. Clinical Trial Design: Statistical Issues, Tim Friede
60.3. Reporting Cardiovascular Clinical Trials, Muthiah Vaduganathan and Scott Solomon
60.4. Principles and methods of intervention research, Jan Tijssen
60.5. Interpretation, Pardeep Jhund and John McMurray
60.6. Meta-analysis, Colin Baigent and Natalie Staplin
Section 61. Environment
61.1. Summary, Thomas Munzel, Sanjay Rajagopalan, Mette Sorensen, Dave Newby, and Robert D. Brook
61.2. Introduction, Thomas Munzel, Sanjay Rajagopalan, Mette Sorensen, Dave Newby, and Robert D. Brook
61.3. Pathophysiology of noise-induced cardiovascular diseases, Thomas Munzel and Mette Sorensen
61.4. Pathophysiology of air pollution-mediated cardiovascular events, Robert D. Brook, David Newby, and Sanjay Rajagopalan
61.5. Epidemiology of traffic noise and cardiometabolic disease, Mette Sorensen and Thomas Munzel
61.6. Epidemiology of air pollution and cardiometabolic diseases, Robert D. Brook, David Newby, and Sanjay Rajagopalan
61.7. Strategies to mitigate cardiovascular effects of noise and air pollution, Thomas Munzel, Sanjay Rajagopalan, Mette Sorensen, Dave Newby, and Robert D. Brook
61.8. Future perspectives, Thomas Munzel, Sanjay Rajagopalan, Mette Sorensen, Dave Newby, and Robert D. Brook
61.9. Conclusions, Thomas Munzel, Sanjay Rajagopalan, Mette Sorensen, Dave Newby, and Robert D. Brook
61.10. Development and challenges over the next decade, Thomas Munzel, Sanjay Rajagopalan, Mette Sorensen, Dave Newby, and Robert D. Brook
Section 62. Occupational and regulatory aspects
62.1. Occupational risk factors for heart disease, Demosthenes G. Katritsis, Mark Anderson, and Michael M. Webb-Peploe
62.2. Regulations concerning individual risk and public safety, Demosthenes G. Katritsis, Mark Anderson, and Michael M. Webb-Peploe
Section 63. Economics and cost-effectiveness
63.1. Introduction to health economics and cost-effectiveness of cardiovascular prevention, Lorenzo Mantovani
63.2. Health and economic impact of non-adherence to preventative cardiovascular medicines, Dyfrig Hughes
63.3. Economics of new therapies in electrophysiology, Giuseppe Boriani, Lucia D’Angiolella, and Fabiana Madotto
63.4. Medical economics and interventional cardiology, Zaher Fanari, Sandra Weiss, and William S. Weintraub
63.5. Economics of new therapies for heart failure, rial fibrillation, and hypercholesterolaemia, Lorenzo Mantovani and Lucia S. D’Angiolella
PART 7. Appendices
A.1. Cardiovascular disease risk estimation, Ian Graham, Marie Therese Cooney, Dirk De Bacquer, and Maryam Kavousi
A.2. Patient reported outcome measures, Polly Mitchell, Andrew Wragg, and Adam Timmis

Recent Posts

Sorry, no posts were found.